Literature DB >> 22743252

MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.

Yuni K Dewaraja1, Eric C Frey, George Sgouros, A Bertrand Brill, Peter Roberson, Pat B Zanzonico, Michael Ljungberg.   

Abstract

In internal radionuclide therapy, a growing interest in voxel-level estimates of tissue-absorbed dose has been driven by the desire to report radiobiologic quantities that account for the biologic consequences of both spatial and temporal nonuniformities in these dose estimates. This report presents an overview of 3-dimensional SPECT methods and requirements for internal dosimetry at both regional and voxel levels. Combined SPECT/CT image-based methods are emphasized, because the CT-derived anatomic information allows one to address multiple technical factors that affect SPECT quantification while facilitating the patient-specific voxel-level dosimetry calculation itself. SPECT imaging and reconstruction techniques for quantification in radionuclide therapy are not necessarily the same as those designed to optimize diagnostic imaging quality. The current overview is intended as an introduction to an upcoming series of MIRD pamphlets with detailed radionuclide-specific recommendations intended to provide best-practice SPECT quantification-based guidance for radionuclide dosimetry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743252      PMCID: PMC3465844          DOI: 10.2967/jnumed.111.100123

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  78 in total

1.  Correction of count losses due to deadtime on a DST-XLi (SmVi-GE) camera during dosimetric studies in patients injected with iodine-131.

Authors:  G Delpon; L Ferrer; A Lisbona; M Bardiès
Journal:  Phys Med Biol       Date:  2002-04-07       Impact factor: 3.609

2.  Dosimetric impact of correcting count losses due to deadtime in clinical radioimmunotherapy trials involving iodine-131 scintigraphy.

Authors:  Ludovic Ferrer; Grégory Delpon; Albert Lisbona; Manuel Bardiès
Journal:  Cancer Biother Radiopharm       Date:  2003-02       Impact factor: 3.099

3.  Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT.

Authors:  Marine Soret; Pierre Malick Koulibaly; Jacques Darcourt; Sébastien Hapdey; Irène Buvat
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

4.  Segmentation of PET volumes by iterative image thresholding.

Authors:  Walter Jentzen; Lutz Freudenberg; Ernst G Eising; Melanie Heinze; Wolfgang Brandau; Andreas Bockisch
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

5.  Recovery of total I-131 activity within focal volumes using SPECT and 3D OSEM.

Authors:  Kenneth F Koral; Anastasia Yendiki; Yuni K Dewaraja
Journal:  Phys Med Biol       Date:  2007-01-16       Impact factor: 3.609

6.  Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture.

Authors:  A Niemierko; M Goitein
Journal:  Radiother Oncol       Date:  1991-03       Impact factor: 6.280

7.  177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.

Authors:  Michael Garkavij; Mattias Nickel; Katarina Sjögreen-Gleisner; Michael Ljungberg; Tomas Ohlsson; Karin Wingårdh; Sven-Erik Strand; Jan Tennvall
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

8.  Regularized reconstruction in quantitative SPECT using CT side information from hybrid imaging.

Authors:  Yuni K Dewaraja; Kenneth F Koral; Jeffrey A Fessler
Journal:  Phys Med Biol       Date:  2010-04-14       Impact factor: 3.609

9.  Dead time of an anger camera in dual-energy-window-acquisition mode.

Authors:  K R Zasadny; K F Koral; F M Swailem
Journal:  Med Phys       Date:  1993 Jul-Aug       Impact factor: 4.071

10.  Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.

Authors:  George Sgouros; Shannon Squeri; Ase M Ballangrud; Katherine S Kolbert; Jerrold B Teitcher; Katherine S Panageas; Ronald D Finn; Chaitanya R Divgi; Steven M Larson; Andrew D Zelenetz
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

View more
  82 in total

1.  Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.

Authors:  A Pfestroff; M Luster; C A Jilg; P J Olbert; C H Ohlmann; M Lassmann; H R Maecke; S Ezziddin; L Bodei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12       Impact factor: 9.236

2.  Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Authors:  Andreas Delker; Wolfgang Peter Fendler; Clemens Kratochwil; Anika Brunegraf; Astrid Gosewisch; Franz Josef Gildehaus; Stefan Tritschler; Christian Georg Stief; Klaus Kopka; Uwe Haberkorn; Peter Bartenstein; Guido Böning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-29       Impact factor: 9.236

3.  Post-reconstruction non-local means filtering methods using CT side information for quantitative SPECT.

Authors:  Se Young Chun; Jeffrey A Fessler; Yuni K Dewaraja
Journal:  Phys Med Biol       Date:  2013-09-07       Impact factor: 3.609

4.  Multi-centre evaluation of accuracy and reproducibility of planar and SPECT image quantification: An IAEA phantom study.

Authors:  Brian E Zimmerman; Darko Grošev; Irène Buvat; Marco A Coca Pérez; Eric C Frey; Alan Green; Anchali Krisanachinda; Michael Lassmann; Michael Ljungberg; Lorena Pozzo; Kamila Afroj Quadir; Mariella A Terán Gretter; Johann Van Staden; Gian Luca Poli
Journal:  Z Med Phys       Date:  2016-04-19       Impact factor: 4.820

Review 5.  Time to demand dosimetry for molecular radiotherapy?

Authors:  D R McGowan; M J Guy
Journal:  Br J Radiol       Date:  2015-01-09       Impact factor: 3.039

Review 6.  SPECT/CT: an update on technological developments and clinical applications.

Authors:  Michael Ljungberg; P Hendrik Pretorius
Journal:  Br J Radiol       Date:  2017-01-16       Impact factor: 3.039

7.  Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Jincheng Shen; Lauren B Smith; Jure Murgic; Hatice Savas; Ehab Youssef; Denise Regan; Scott J Wilderman; Peter L Roberson; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2014-05-19       Impact factor: 10.057

8.  A no-gold-standard technique for objective assessment of quantitative nuclear-medicine imaging methods.

Authors:  Abhinav K Jha; Brian Caffo; Eric C Frey
Journal:  Phys Med Biol       Date:  2016-03-16       Impact factor: 3.609

9.  Radiopharmaceutical Therapy.

Authors:  George Sgouros
Journal:  Health Phys       Date:  2019-02       Impact factor: 1.316

10.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.